摘要
目的 探讨原发性肝癌患者血浆尿激酶 (uPA)和可溶性尿激酶受体 (suPAR)在其临床分期、分型、肝功能分级等方面的临床意义。方法 采用ELISA法分别检测肝癌、肝硬化患者血浆uPA和suPAR的水平 ,分别和正常对照组比较 ,同时将肝癌患者的uPA和suPAR值作直线相关分析 ,并按原发性肝癌的临床分期、分型和肝功能分级标准进行分组比较。结果 肝癌和肝硬化患者血浆uPA和suPAR水平均分别高于正常对照组 (P <0 .0 1 ) ;肝癌患者血浆uPA和suPAR之间呈正相关性 (r=0 .4 84 4 ,P <0 .0 1 )。肝癌Ⅰ、Ⅱ、Ⅲ期患者的血浆uPA和suPAR水平均分别依次升高 ,其中Ⅲ期显著高于Ⅰ期和Ⅱ期 (P <0 .0 5 )。结论 原发性肝癌和肝硬化患者血浆uPA和suPAR水平呈升高趋势 ,以前者升高更明显 ,说明存在纤溶激活状态 ;在肝癌患者中 ,这两项水平的升高与临床分期有关 。
Objective To elucidate the clinical significance of plasma urokinase-type plasminogen activator(uPA) and its soluble receptor (suPAR) levels in clinical staging,typing of primary hepatocelluar carcinoma(HCC). Methods\ Plasma levels of uPA and suPAR were measured by using ELISA in cases of HCC and liver cirrhosis, compared with normal controls respectively. Results The plasma uPA and suPAR levels in HCC and liver cirrhosis were significantly higher than that of normal controls respectively(P<0.01); A positive linear correlation between plasma uPA and suPAR levels of HCC cases was established(r= 0.484 4 ,P<0.01).The plasma uPA and suPAR levels of HCC at stage Ⅰ,Ⅱ,Ⅲ were elevated in order of precedence respectively,in which a significantly higher levels in stage Ⅲ than stage Ⅰ or stage Ⅱ.Conclusions The elevation of plasma uPA and suPAR levels is associated with clinical stages,disease progression and prognosis.
出处
《医师进修杂志》
北大核心
2004年第6期21-22,26,共3页
Journal of Postgraduates of Medicine
关键词
原发性肝癌
尿激酶
可溶性受体
临床分期
临床分型
肝功能分级
primary hepatocelluar carcinoma
urokinase-type plasminogen activator
soluble receptor
clinical stages
clinical types
Child-pugh grades
